6/28/23, 10:57 PM Gujjar Pathway Feedback Search Clinical Topics Home Studies Gujjar Gujjar Disease Status epilepticus Trial question What is the role of intravenous levetiracetam in patients with status epilepticus and cluster seizures? Study design Single center Open label RCT Population Characteristics of study participants 32.0% female N = 115 68.0% male 115 patients (37 female, 78 male) Inclusion criteria: adult patients with status epilepticus or cluster seizures, following an initial dose of IV benzodiazepine to control ongoing seizure Key exclusion criteria: known allergy to drugs used, requiring immediate neurosurgery, hemodynamic compromise, serious arrhythmias, pregnancy, cardiac failure or pulmonary edema, in pre-terminal states, or having pseudo-seizures Interventions N=22 + 38 levetiracetam (intravenous dosage of 30 mg/kg over 30 min for status epilepticus and cluster seizures) N=30 + 25 phenytoin (intravenous dosage of 20 mg/kg over 30 min for status epilepticus and cluster seizures) Primary outcome https://web.pathway.md/studies/reck4zFlasiYQFPzL 1/2 6/28/23, 10:57 PM Gujjar Pathway Seizure control over 24 hour 82.0 % 82 73.3 61.5 % 41.0 % 20.5 % No significant difference 0.0 % Levetiracetam Phenytoin No significant difference in seizure control over 24 hour (82% vs. 73.3%; RR 1.12, 95% CI -1.11 to 3.35) Secondary outcomes No significant difference in poor outcome with modified Rankin score 4-6 (45% vs. 60%; RR 0.75, 95% CI -0.63 to 2.13) Safety outcomes No significant difference in adverse events. Conclusion In adult patients with status epilepticus or cluster seizures, following an initial dose of IV benzodiazepine to control ongoing seizure, levetiracetam was not superior to phenytoin with respect to seizure control over 24 hour. Reference Arunodaya R Gujjar, Ramachandiran Nandhagopal, Poovathoor C Jacob et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure. 2017 Jul;49:8-12. Open reference URL https://web.pathway.md/studies/reck4zFlasiYQFPzL 2/2